Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 May 17;12(5):1115.
doi: 10.3390/biomedicines12051115.

IFN-γ, IL-17A, IL-4, and IL-13: Potential Biomarkers for Prediction of the Effectiveness of Biologics in Psoriasis Patients

Ching-Liang Hsieh  1   2 , Sheng-Jie Yu  3 , Kuo-Lung Lai  4 , Wei-Ting Chao  5 , Chung-Yang Yen  6   7   8
Affiliations

IFN-γ, IL-17A, IL-4, and IL-13: Potential Biomarkers for Prediction of the Effectiveness of Biologics in Psoriasis Patients

Ching-Liang Hsieh et al. Biomedicines. .

Abstract

Biologics are widely used to treat moderate-to-severe psoriasis. However, we have unmet needs for predicting individual patient responses to biologics before starting psoriasis treatment. We investigate a reliable platform and biomarkers for predicting individual patient responses to biologics. In a cohort study between 2018 and 2023 from a referral center in Taiwan, twenty psoriasis patients with or without psoriatic arthritis who had ever experienced two or more biologics were enrolled. Peripheral blood mononuclear cells obtained from these patients were treated with Streptococcus pyogenes and different biologics. The PASI reduction rate was strongly correlated with the reduction rate in the IL-13 level (p = 0.001) and the ratios of IFN-γ to IL-13 (p < 0.001), IFN-γ to IL-4 (p = 0.019), and IL-17A to IL-13 (p = 0.001). The PASI reduction difference was strongly correlated with the difference in the IFN-γ level (p = 0.002), the difference in the ratios of IFN-γ to IL-4 (p = 0.041), the difference in the ratios of IFN-γ to IL-13 (p = 0.006), the difference in the ratios of IL-17A to IL-4 (p = 0.011), and the difference in the ratios of IL-17A to IL-13 (p = 0.029). The biomarkers IFN-γ, IL-13, IFN-γ/IL4, IFN-γ/IL13, IL-17A/IL-4, and IL-17A/IL-13 are representative of the effectiveness of psoriasis treatment.

Keywords: biologics; biomarker; psoriasis.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
PBMCs isolated from psoriasis patients (n = 5) incubated with 5 × 106, 1 × 107, and 2 × 107 CFU S. pyogenes for 24 h. Cell viability was measured by an MTT assay.
Figure 2
Figure 2
Correlation between clinical PASI and biomarkers among different biologics. Heatmaps showing correlation coefficients with different colors and p values with stars. (A) Reduction ratios of PASI and biomarkers for ustekinumab. (B) Reduction difference of PASI and biomarkers for ustekinumab. (C) Reduction ratios of PASI and biomarkers for adalimumab. (D) Reduction difference of PASI and biomarkers for adalimumab. * p < 0.05, ** p < 0.01, *** p < 0.001.
Figure 3
Figure 3
Suggested protocol for biologic selection before psoriasis treatment.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Parisi R., Iskandar I.Y.K., Kontopantelis E., Augustin M., Griffiths C.E.M., Ashcroft D.M., Global Psoriasis Atlas National, regional, and worldwide epidemiology of psoriasis: Systematic analysis and modelling study. BMJ. 2020;369:m1590. doi: 10.1136/bmj.m1590. - DOI - PMC - PubMed
    1. Merola J.F., Perez Chada L.M., Siegel M., Bagel J., Evans C., Lockshin B., Mason M., Guo N., McLean R.R., Greenberg J.D., et al. The National Psoriasis Foundation psoriasis treatment targets in real-world patients: Prevalence and association with patient-reported outcomes in the Corrona Psoriasis Registry. J. Eur. Acad. Dermatol. Venereol. 2020;34:2051–2058. doi: 10.1111/jdv.16274. - DOI - PubMed
    1. Caiazzo G., Fabbrocini G., Di Caprio R., Raimondo A., Scala E., Balato N., Balato A. Psoriasis, Cardiovascular Events, and Biologics: Lights and Shadows. Front. Immunol. 2018;9:1668. doi: 10.3389/fimmu.2018.01668. - DOI - PMC - PubMed
    1. Mohd Noor A.A., Azlan M., Mohd Redzwan N. Orchestrated Cytokines Mediated by Biologics in Psoriasis and Its Mechanisms of Action. Biomedicines. 2022;10:498. doi: 10.3390/biomedicines10020498. - DOI - PMC - PubMed
    1. Armstrong A.W., Puig L., Joshi A., Skup M., Williams D., Li J., Betts K.A., Augustin M. Comparison of Biologics and Oral Treatments for Plaque Psoriasis: A Meta-analysis. JAMA Dermatol. 2020;156:258–269. doi: 10.1001/jamadermatol.2019.4029. - DOI - PMC - PubMed

LinkOut - more resources